Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 263 participants.
Also called NCT02960204
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 263 participants
- Sponsor
- Histogen
- Registry
-
NCT02960204
-
- Main results
- Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Germany, Spain
- Registry status
- Completed
Technical summary
Registry record NCT02960204. Randomized; triple masking; primary purpose treatment. Start 2016-10-17 (actual); primary completion 2018-10-02 (actual). Results posted on 2022-01-14.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension
- Acronym
- ENCORE-PH
- Condition
- Cirrhosis
- Condition
- Portal Hypertension
- Condition
- Non-alcoholic Steatohepatitis
- Intervention (Drug)
- Emricasan
- Intervention (Drug)
- Placebo
- Lead sponsor
- Histogen
Record details
- Record id
cardio:ct-nct02960204- Content hash
580cca8b994119a868336430f69c699dcdf1539366f06ec3b25c97e1f11a0431